Business Context and Reporting Period
Company: Alumis Inc. (ALMS)
Filing Type: Form 8-K (Current Report)
Date of Report: January 2, 2026
Event: Issuance of a Notice of Material Breach and Notification of Claim for Indemnification to Climb Bio, Inc. regarding a failed milestone payment under an Asset Purchase Agreement (APA).
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The filing focuses exclusively on a specific contractual dispute.
- Disputed Amount: $3,000,000 (Development Milestone payment due January 1, 2026).
- Total Potential Obligations (per Climb Bio prior filings): Up to $157.5 million in milestone payments, plus single-digit royalties and sublicense payments.
Material Changes and Events
On January 2, 2026, Alumis Inc. and its subsidiary Acelyrin, Inc. notified Climb Bio, Inc. of a material breach of the APA dated January 11, 2024. Climb Bio refused to pay the $3,000,000 milestone, claiming the drug candidate "budoprutug" does not constitute a "Product" under the agreement. This follows a declaratory judgment action filed by Climb Bio in Delaware Superior Court on December 31, 2025.
Outlook, Risks, and Management Commentary
Management Intent: Alumis intends to pursue all available rights and remedies, including seeking the $3,000,000 payment with interest, indemnification for attorneys' fees and costs, and other relief.
Risks and Contingencies:
- Litigation Uncertainty: The outcome of the legal dispute is inherently uncertain and could materially affect the Company's ability to obtain payments.
- Contractual Dispute: Climb Bio's legal position contradicts Alumis's interpretation of the APA and Climb Bio's own prior SEC filings.
- Forward-Looking Statements: The Company disclaims any obligation to update statements regarding the litigation or expected recovery.
Investor Verification Checklist
- Verify the status of the declaratory judgment action filed by Climb Bio in Delaware Superior Court on December 31, 2025.
- Review the specific definition of "Product" in the January 11, 2024 Asset Purchase Agreement to assess the validity of Climb Bio's defense.
- Monitor future filings for updates on the litigation timeline and any potential settlement discussions.
- Assess the impact of the $3,000,000 receivable and potential legal costs on the Company's cash flow and balance sheet.